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Objectives The purpose of this study was to determine whether patients taking aspirin before an acute coronary syndrome
(ACS) are at higher risk of recurrent events or mortality.
Background Controversy exists whether prior aspirin use is an independent predictor of worse outcomes in patients who
experience an ACS.
Methods We evaluated 66,443 ACS patients from a merged database of previous Thrombolysis in Myocardial Infarction
trials. We evaluated the differences in ACS type, total mortality, and the composite end point of death, myocar-
dial infarction (MI), recurrent ischemia, or stroke between prior aspirin and nonprior aspirin users. We used mul-
tivariate analysis to control for differences in baseline characteristics.
Results Prior aspirin users (n  17,839) were older (63 years vs. 59 years) and had more coronary risk factors and evi-
dence of coronary artery disease (MI, angina, prior intervention) than nonprior aspirin users (n  48,604) (all
p  0.0001). Prior aspirin use was associated with less severe types of ACS at presentation (e.g., unstable
angina  non–ST-segment elevation MI  ST-segment elevation MI) than their nonaspirin user counterparts
(p  0.0001). After multivariate analysis, there was no difference in total mortality between prior aspirin users
and nonaspirin users at day 30 (odds ratio [OR]: 1.01; 95% confidence interval [CI]: 0.90 to 1.13) or by the last
follow-up visit (mean 328 days) (hazard ratio: 1.03; 95% CI: 0.95 to 1.11). Prior aspirin use was modestly asso-
ciated with recurrent MI (OR: 1.26; 95% CI: 1.12 to 1.43) and the composite end point (OR: 1.16; 95% CI: 1.08
to 1.24).
Conclusions Prior aspirin use was associated with more comorbidities and coronary disease and a higher risk of recurrent MI,
but not mortality. As such, it should best be considered a marker of a patient population at high risk for recur-
rent adverse events after ACS. (J Am Coll Cardiol 2010;56:1376–85) © 2010 by the American College of Car-
diology Foundationp
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Aspirin has been shown to be beneficial in the primary
revention, secondary prevention, and treatment of acute
oronary syndromes (ACS) because of the important role of
latelets in thrombus formation (1–8). Despite these proven
enefits, some recent studies have suggested that prior
spirin use by those who develop an ACS may actually
redispose to worse outcomes than those not previously
aking aspirin (9–11). This apparent “aspirin paradox” has
esulted in much controversy without clear explanation.
lthough “aspirin resistance” might be an explanation of
oor outcomes of prior aspirin users, these phenomena
ppear to impact only a small percentage of these patients
12,13). Alternatively, prior aspirin use may be a marker of
high-risk cohort of patients in whom aspirin therapy
imply does not suffice to completely prevent future cardio-
ascular events.
To help clarify this issue, we sought to determine the
elationship of prior aspirin use on the presentation and
hort- and long-term outcomes of more than 66,000 pa-
ients with ACS in the merged database of the TIMI
Thrombolysis In Myocardial Infarction) trials. We hypoth-
sized that prior aspirin use is not an independent predictor
f adverse outcomes in patients with ACS, but rather serves
s a marker of high risk.
ethods
atient population and data collection. A merged data-
ase consisting of 66,443 patients with ACS was created, cooling the data from the following 16 prospective, multi-
enter, randomized, placebo controlled trials: TIMI IIIB,
IMI 4, TIMI 10A, TIMI 10B, TIMI 14, OPUS–TIMI 16
Oral Glycoprotein IIb/IIIa inhibition with orofiban in patients
ith unstable coronary syndromes), InTIME II–TIMI 17
Intravenous nPA for the treatment of infarcting myocar-
ium), TACTICS–TIMI 18 (Treat angina with Aggrastat
nd determine cost of therapy with an invasive or conservative
trategy), INTEGRITI–TIMI 20 (Integrilin and tenecteplase
n acute myocardial infarction), A2Z–TIMI 21, PROVE IT–
IMI 22 (Pravastatin or atorvastatin evaluation and infection
herapy), ENTIRE–TIMI 23 (Enoxaparin as adjunctive anti-
hrombin therapy), FASTER–TIMI 24 (Fibrinolytics and
ggrastat ST-Elevation Resolution Trial), EXTRACT–
IMI 25 (Enoxaparin and thrombolysis reperfusion for acute
yocardial infarction treatment), JUMBO–TIMI 26 (Joint
tilization of medications to block platelets optimally), and
LARITY–TIMI 28 (Clopidogrel and adjunctive reperfusion
herapy). The details of these studies, including inclusion and
xclusion criteria, have been previously described (14–30) and
re briefly summarized in the Online Appendix. Randomiza-
ion of patients into the aforementioned trials occurred be-
ween October 1989 (TIMI IIIB) through October 2005
EXTRACT–TIMI 25), with the follow-up for the trial-
pecific duration for generally up to 1 year. All patients enrolled
n the studies were at least 18 years of age, met criteria for an
CS (unstable angina [UA], non–ST-segment elevation myo-ardial infarction [NSTEMI], or ST-segment elevation myo-
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Prior Aspirin and ACS Prognosis October 19, 2010:1376–85cardial infarction [STEMI]), and
had documentation of prior or no
prior aspirin use.
In each trial, the institutional
review board at each participat-
ing center approved the protocol,
and informed consent was ob-
tained from all patients enrolled.
Patient data were collected from
the medical record, entered into
the trial case report form, and
ultimately were stored in a mas-
ter TIMI database. Prior aspirin
use was defined from the case
report form as regular aspirin use
for at least 1 week before presen-
tation. Aspirin received immedi-
ately before hospitalization or in
the emergency department was
not considered prior aspirin use.
Efficacy end points in this study
include total mortality, recurrent
myocardial infarction (MI), recur-
rent ischemia requiring hospital-
ization (RI), ischemia requiring
urgent revascularization (UR), and
stroke. Definitions were generally
the standard TIMI definitions,
nd most trials had a clinical end point committee that adjusted
he primary end points.
tatistical analysis. Baseline demographic characteris-
ics, past medical history, features of clinical presenta-
ion, and clinical outcomes were compared for those
atients who had used aspirin before admission (prior
spirin users) and those who had not (nonaspirin users).
tatistical analyses were conducted using the Wilcoxon
ank sum test for continuous variables and the Pearson
hi-square test for categorical variables. The clinical
utcomes assessed at 30 days and during last follow-up
ncluded death, MI, death/MI, and a composite of
eath/recurrent MI/UR/RI/stroke. Logistic regression
as used for 30-day outcomes, and Cox proportional
azards regression was used for long-term outcomes.
In order to assess the independent association of prior
spirin use with clinical outcomes, a multivariate model was
onstructed incorporating covariates from the univariate
nalyses that differed significantly (p  0.05) between the
rior aspirin users and the nonaspirin users. Specifically, we
ncluded variables in the model that predicted prior aspirin
se and variables that predicted the outcomes of interest.
hese variables included age, sex, diabetes, hypertension,
urrent smoker, prior MI, history of angina, history of
ercutaneous coronary intervention (PCI), history of coro-
ary artery bypass grafting (CABG), history of cerebrovas-
ular accident, history of congestive heart failure, Killip class
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
CI  confidence interval
HR  hazard ratio
MI  myocardial infarction
NSTEMI  non–ST-
elevation myocardial
infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
RI  recurrent ischemia
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
UA  unstable angina
UR  urgent
revascularizationto 4, index ACS event, prior medications, medications und procedures during hospitalization, ST-segment devia-
ion, and elevated cardiac markers. Backwards selection was
erformed on the full model with a threshold of p  0.05.
he final model included only covariates left after the
election process. Survival analysis was performed using the
aplan-Meier method. Mortality curves were generated
eparately for prior aspirin users and nonaspirin users, and
he curves were compared using the log-rank test. All
nalyses were performed using STATA version 9.2
STATA Corp., College Station, Texas).
esults
tudy population. A total of 66,443 patients with a diag-
osis of ACS served as the study sample. Their baseline
emographic and clinical characteristics are shown in Table 1.
mong them, 26.8% were identified as prior aspirin users.
rior aspirin use was associated with substantially more
igh-risk features for adverse outcomes than nonaspirin use.
rior aspirin users were, on average, approximately 3.5 years
lder, had more coronary artery disease (CAD) risk factors
e.g., diabetes, hypertension, hyperlipidemia, family history
f MI), and more frequently had previous angina, CAD,
I, PCI, CABG, congestive heart failure, and cerebrovas-
ular accident (all p  0.0001). A higher percentage of
atients enrolled from the U.S. were prior aspirin users
ompared with patients enrolled from outside the U.S.
41.2% vs. 22.9%; p  0.001). Prior aspirin users were also
ore likely than nonaspirin users to be taking other cardio-
ascular medications preceding their presentation with an
CS, including statins, beta-blockers, angiotensin-converting
nzyme inhibitors, calcium-channel blockers, and nitrates.
oth TIMI UA/NSTEMI (31) and STEMI risk scores
32) were higher in prior aspirin users than nonaspirin users
p 0.0001). Prior aspirin users were also less likely to have
ositive biomarkers (65.5% vs. 85.1%; p  0.0001) and
T-segment deviation (67.0% vs. 77.7%; p  0.0001) than
onaspirin users at the time of initial presentation. In
ontrast, prior aspirin users were less likely than nonaspirin
sers to be active smokers (29.6% vs. 48.1%).
ype of ACS presentation. The type of ACS at presen-
ation appeared less severe in prior aspirin users than in
onaspirin users. A subset analysis of 18,637 patients (n 
,824 prior aspirin users; n  11,813 nonaspirin users) who
nrolled in trials that included patients across the entire
CS spectrum (UA, NSTEMI, and STEMI) was per-
ormed (19,20,24) (Fig. 1). Among patients with prior
spirin use, the most common presentation was unstable
ngina, and the least common was STEMI. The converse
as the case for nonaspirin users. These differences in the
everity of the presentation of the index ACS among the 2
roups were statistically significant (all p  0.0001). Using
ultivariate analysis correcting for all baseline differences
etween the prior aspirin and nonaspirin users, prior aspirin
se was an independent predictor of less severe ACS at
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October 19, 2010:1376–85 Prior Aspirin and ACS Prognosisresentation (odds ratio [OR]: 0.59; 95% CI: 0.54 to 0.64
or STEMI vs. UA/NSTEMI) and (OR: 0.57; 95% CI:
.52 to 0.63 for NSTEMI vs. UA).
ngiographic findings. In a subset of 10,003 patients from
hose trials mandating angiography at index hospitalization
TIMI IIIB, 4, 10A, 10B, 14, 18, 20, 23, 24, 28)
14,16,17,21–23,25–28), prior aspirin use was associated
ith more 3-vessel coronary disease, defined as coronary
aseline and Clinical Characteristics ofti nts Previously Using nd No Using AspirinTable 1 Base ine a d Clinical Characteristics ofPatients Previously Using and Not Using Aspirin
Prior Aspirin Use No Prior Aspirin
Patients, n (%) 17,839 (26.8%) 48,604 (73.2%)
Mean age (yrs) 62.6 59.0
Age 65 yrs 46.1 34.4
Male sex 74.2 75.7
History of DM 23.3 14.6
History of HTN 56.8 36.5
Current smokers 29.6 48.1
History of dyslipidemia 49.9 19.9
Family history of CAD 39.6 30.8
Prior MI 45.6 7.90
Prior angina 54.7 21.1
Prior PCI 21.4 2.1
Prior CABG 13.3 1.2
Prior CAD 80.0 28.2
Prior stroke 3.5 0.8
Prior CHF 7.6 2.1
Killip class II to IV 12.1 9.7
Prior atrial fibrillation 3.6 3.0
Statins 29.7 5.6
Beta-blockers 46.1 14.5
ACE inhibitors 30.8 13.9
Calcium-channel blockers 29.2 10.6
Nitrates 38.4 10.2
Clopidogrel/ticlopidine 2.0 0.6
Warfarin 0.5 0.4
Index event UA 51.1 22.9
Index event NSTEMI 28.1 33.7
Index event STEMI 20.8 43.4
ST-segment deviation 67.0 77.7
Elevated biomarkers (CK-MB or troponin) 65.5 85.1
TIMI UA/NSTEMI risk score
0–2 20.6 59.5
3–4 63.5 37.6
5–7 15.8 2.9
TIMI STEMI risk score
0–2 41.1 54.0
3–5 44.3 37.0
6–8 12.8 8.3
8 1.8 0.7
Enrolled in U.S. 29.3 14.9
alues are percentages unless otherwise indicated. All p values  0.0001 except for prior atrial
brillation which was p  0.03 and prior warfarin which was p  0.015.
ACE angiotensin-converting enzyme; CABG coronary artery bypass grafting; CAD coronary
rtery disease; CHF  congestive heart failure; CK-MB  creatine kinase-myocardial band; DM 
iabetes mellitus; HTN  hypertension; MI  myocardial infarction; NSTEMI  non–ST-segment
levation MI; PCI  percutaneous coronary intervention; Prior CAD  prior MI, PCI, CABG, or
rial-defined history of CAD; UA  unstable angina; STEMI  ST-segment elevation MI; TIMI 
hrombolysis In Myocardial Infarction.tenoses 50% and more left main coronary artery disease
VTable 2). This was true both for patients with UA/
STEMI and STEMI.
anagement of the index ACS. There were differences
etween prior aspirin and nonaspirin users in the initial
anagement of the index ACS (Table 3). Prior aspirin users
ere more likely than nonaspirin users to undergo a revas-
ularization procedure during the initial hospitalization,
ither a PCI or CABG (34.7% vs. 29.0%; p 0.0001). This
tatistically significant difference remained after stratifying
y type of ACS event. Although many small but statistically
51.1%
28.1%
20.8% 22.9%
33.7%
43.4%
0%
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80%
%
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Figure 1
Association Between Prior Aspirin Use and Type
of ACS at Presentation Among Patients Enrolled
in the TIMI Trials
Prior aspirin users were diagnosed with less severe acute coronary syndrome
(ACS) presentations (unstable angina [UA]  non–ST-segment elevation myo-
cardial infarction [NSTEMI]  ST-segment elevation myocardial infarction
[STEMI]), whereas the opposite was seen in nonaspirin users (STEMI 
NSTEMI  UA) (p  0.0001).
ngiographic Findings of Patientsreviously Using a d N t Using AspirinTable 2 A iographic Findi g of PatientsPreviously Using and Not Using Aspirin
Prior Aspirin Use No Prior Aspirin
Angiography performed, n (%) 3,063 (85.7%) 6,940 (92.5%)
UA/NSTEMI
Diseased vessels
None 10.5 14.2
1 25.6 30.4
2 31.3 28.3
3 32.7 27.1
Left main 9.6 7.2
STEMI
Diseased vessels
None 2.2 3.7
1 34.7 47.9
2 36.1 31.6
3 27.0 16.8
Left main 5.5 2.9alues are percentages. All p values 0.0001 except for UA/NSTEMI left main, p  0.041.
Abbreviations as in Table 1.
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Prior Aspirin and ACS Prognosis October 19, 2010:1376–85ignificant differences in prescribed medications were seen,
ost notable was that prior aspirin users were more likely
han nonaspirin users to be treated with a glycoprotein
Ib/IIIa inhibitor during hospitalization (38.3% vs. 21.3%;
 0.0001).
nadjusted clinical outcomes. At day 30, there was no
ifference in total mortality between prior aspirin and
onaspirin users (4.8% vs. 4.7%; p  0.68) (Fig. 2). A
igher rate of the unadjusted composite end point of death,
ecurrent MI, RI, UR, and stroke was seen in prior aspirin
sers (21.5% vs. 17.7%; p  0.0001). There was also a
igher rate of TIMI major and minor bleeding in the prior
spirin group (5.0% vs. 3.7%; p  0.0001) (Table 4).
hrough the last follow-up visit (mean 328 days), higher
nadjusted rates of total mortality (9.0% vs. 7.0%), recurrent
I (9.0% vs. 6.0%), and the composite end point of death,
ecurrent MI, RI, UR, and stroke (32.9% vs. 27.0%) were
een in the prior aspirin group (all p  0.0001) (Table 5).
djusted clinical outcomes. Using multivariate analyses
orrecting for all baseline differences between the prior
spirin and nonaspirin users, there was no difference in
djusted total mortality at day 30 (OR: 1.01; 95% CI: 0.90
o 1.13) (Fig. 3). Similarly, no difference was observed in
djusted total mortality through the last follow-up visit
hazard ratio [HR]: 1.03; 95% CI: 0.95 to 1.11) between
rior aspirin and nonaspirin users (Fig. 4). Independent
Management of the ACS According to Prior AspTable 3 Management of the ACS According
Prior Asp
Patients, n (%) 17,839
Procedures performed
PCI 28
CABG 7
Either PCI or CABG 34
Medications during hospitalization
Aspirin 96
Statins 60
Beta-blockers 75
ACE inhibitors 53
Calcium-channel blockers 16
Nitrates 67
Clopidogrel/ticlopidine 30
Warfarin 2
Heparin/enoxaparin 95
Glycoprotein IIb/IIIa inhibitor 38
Medications at hospital discharge
Aspirin 92
Statins 61
Beta-blockers 64
ACE inhibitors 47
Calcium-channel blockers 14
Nitrates 37
Clopidogrel/ticlopidine 30
Warfarin 2
Values are percentages unless otherwise indicated.
ACS  acute coronary syndrome; other abbreviations as in Table 1redictors of mortality at day 30 and last follow-up visit bncluded Killip class, STEMI, ST-segment deviation,
nd elevated cardiac biomarkers (all p  0.0001), but not
rior aspirin use (Figs. 3 and 4). However, prior aspirin
se was associated with a significantly increased risk of
ecurrent MI on day 30 and through the last follow-up
isit (OR: 1.26, 95% CI: 1.12 to 1.43; and HR: 1.24, 95%
I: 1.12 to 1.37). Prior aspirin use was also associated
ith the composite end point of death, recurrent MI, RI,
R, and stroke at both day 30 and through the last
ollow-up visit (OR: 1.16, 95% CI: 1.08 to 1.24; and HR:
.08, 95% CI: 1.03 to 1.13).
iscussion
sing the TIMI database involving 16 ACS trials with
6,443 patients, our analysis demonstrates that prior aspirin
se identified a high-risk patient population possessing
ubstantial comorbidities. This group of patients had an
nadjusted higher rate of death and cardiovascular events.
owever, after adjustment for baseline characteristics, prior
spirin use did predict recurrent MI and ischemic events,
ut was not an independent predictor of total mortality after
n ACS. As such, prior aspirin use should best be consid-
red a marker of a patient population at high risk for
ecurrent adverse events after ACS.
There is little controversy whether the use of antithrom-
serior Aspirin Use
se No Prior Aspirin p Value
) 48,604 (73.2%) 0.0001
25.6 0.0001
3.6 0.0001
29.0 0.0001
98.9 0.0001
55.2 0.0001
81.1 0.0001
58.8 0.0001
8.1 0.0001
70.0 0.0001
27.3 0.0001
3.5 0.0001
96.8 0.0001
21.3 0.0001
91.3 0.003
60.6 0.011
71.1 0.0001
56.4 0.0001
7.1 0.0001
34.2 0.0001
30.6 0.544
2.2 0.325irin Uto P
irin U
(26.8%
.2
.0
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October 19, 2010:1376–85 Prior Aspirin and ACS Prognosisent of ACS. Where some controversy does exist, however,
s whether prior aspirin use, seemingly paradoxically, is an
ndependent predictor of worse clinical outcomes after ACS
r whether it, instead, represents a marker for patients at
igher risk. For example, in an analysis of the PURSUIT
Platelet Glycoprotein IIb/IIIa in Unstable Angina: Recep-
or Suppression Using Integrilin Therapy) trial, Alexander
t al. (9) report that prior aspirin use in patients with
A/NSTEMI was associated with a modest increase in the
omposite end point of death or MI at days 4 and 30
ost-ACS (OR: 1.16; 95% CI: 1.00 to 1.33). Subsequently,
0
.0
0
0
.0
2
0
.0
4
0
.0
6
0
.0
8
0
.1
0
0
.1
2
07 30 90 180 270 365
analysis time
No prior a
Figure 2 Kaplan-Meier Survival Curves Relating Unadjusted Tot
Between Prior Aspirin Users and Nonaspirin Users Aft
Despite significantly more high-risk features among prior aspirin users (blue), there wa
(p  0.68). By the last follow-up visit (day 328), however, prior aspirin users had a
Clinical Outcomes at Day 30 According to PriorTable 4 Clinical Outcomes at Day 30 Accor
Prior Aspir
Use, %
Efficacy
Death 4.8
MI 5.1
UR 7.1
RI 11.5
Stroke 1.1
Death/MI 9.2
Death/MI/UR 15.4
Death/MI/UR/RI/stroke (including ICH) 21.5
Safety
ICH 0.5
TIMI major bleed 2.3
TIMI minor bleed 3.1
TIMI major/minor bleed 5.0ICH intracranial hemorrhage; MImyocardial infarction; OR odds ratio; R
UR  urgent revascularization.nalysis of the TIMI 11B trial by Santopinto et al. (11)
ound that prior aspirin use was associated with more
ecurrent MI at days 8 and 43 than non–prior aspirin users
n patients with UA/NSTEMI. Similarly, Lancaster et al.
10) reported an increase in the composite end point of
eath/recurrent MI/RI at days 7 and 14 post-ACS in
atients on prior aspirin therapy. None of these studies,
owever, demonstrated an independent association between
rior aspirin use and increased mortality. Moreover, only
hort-term adverse outcomes (namely recurrent MI) were
ssociated with prior aspirin use in these analyses.
540 630 720 810 900
 following ACS)
Prior aspirin
ortality Rates
Acute Coronary Syndrome
ifference in total mortality at day 30 as compared with nonaspirin users (red)
ease in unadjusted total mortality as compared with nonusers (p  0.0001).
rin Useto Prior Aspirin Use
No Prior
Aspirin, %
Unadjusted OR
(p Value)
Adjusted OR
(p Value)
4.7 1.02 (0.68) 1.01 (0.90)
3.5 1.46 (0.0001) 1.26 (0.0001)
6.4 1.13 (0.001) 1.07 (0.20)
9.2 1.28 (0.0001) 1.21 (0.0001)
1.2 0.96 (0.59) 1.04 (0.65)
7.8 1.20 (0.0001) 1.12 (0.01)
13.1 1.21 (0.0001) 1.06 (0.11)
17.7 1.28 (0.0001) 1.16 (0.0001)
0.6 0.82 (0.11) 1.04 (0.78)
1.7 1.34 (0.0001) 1.07 (0.39)
2.3 1.38 (0.0001) 1.08 (0.22)
3.7 1.35 (0.0001) 1.08 (0.14)450
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Prior Aspirin and ACS Prognosis October 19, 2010:1376–85More recent analyses have arrived at conclusions in
onflict with those in the aforementioned studies. Spen-
er et al. (33) analyzed ACS patients in the GRACE
Global Registry of Acute Coronary Events) registry and
ound that in patients with a history of CAD, prior
spirin use was associated with a lower total mortality and
ther short-term adverse outcomes during the index
ospitalization. Portnay et al. (34) analyzed a large
egistry of Medicare patients with a diagnosis of acute MI
nd found that prior aspirin use was associated with fewer
eaths at both 1 and 6 months after an ACS. They also
Clinical Outcomes at Last Follow Up Visit(Mean 328 Days) According t Prior Aspirin UseTable 5 Clinical Outcomes at Last Follow U(Mean 328 Days) According to Prio
Prior Aspir
Use, %
Efficacy
Death 9.0
MI 9.0
UR 11.2
RI 19.9
Stroke 1.9
Death/MI 16.6
Death/MI/UR 23.9
Death/MI/UR/RI/stroke (including ICH) 32.9
Safety
ICH 0.6
TIMI major bleed 2.9
TIMI minor bleed 3.3
TIMI major/minor bleed 6.1
Abbreviations as in Table 4.
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Figure 3 Adjusted Odds Ratio of 30-Day Mortality Among 66,4
Adjusted odds ratios and 95% confidence intervals are shown. Variables from the
model before stepwise backwards selection. CHF  congestive heart failure; DM 
segment elevation myocardial infarction.emonstrated a lower risk of recurrent MI at 6 months in
rior aspirin users but found no difference in recurrent
I at day 30. An analysis by Soiza and Leslie (35)
ssessed outcomes post-ACS among prior users of aspirin
lone, prior users of clopidogrel alone, and prior users of
spirin plus clopidogrel. The results, unadjusted for
omorbid conditions, showed that prior aspirin plus
lopidogrel use was associated with the worst outcomes
ost-ACS among the 3 groups (35).
Our study highlights the role of confounding comorbid
onditions (in particular, confounding by indication) in
it
irin Use
No Prior
Aspirin, %
Unadjusted HR
(p Value)
Adjusted HR
(p Value)
7.0 1.22 (0.0001) 1.03 (0.47)
6.0 1.48 (0.0001) 1.24 (0.0001)
9.6 1.15 (0.0001) 1.03 (0.52)
14.7 1.34 (0.0001) 1.08 (0.04)
1.7 1.08 (0.31) 1.11 (0.20)
13.3 1.22 (0.0001) 1.07 (0.05)
20.2 1.16 (0.0001) 1.03 (0.35)
27.0 1.19 (0.0001) 1.08 (0.002)
0.7 0.82 (0.11) 1.02 (0.88)
2.0 1.39 (0.0001) 1.00 (0.98)
2.4 1.38 (0.0001) 1.08 (0.23)
4.6 1.34 (0.0001) 1.10 (0.06)
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October 19, 2010:1376–85 Prior Aspirin and ACS Prognosisxplaining the higher unadjusted rate, but lack of a differ-
nce in the adjusted rate of mortality. For example, nearly
0% of prior aspirin users had a history of CAD com-
ared with only 28.2% in nonusers. Also, nearly one-half
f the prior aspirin users had a history of a previous MI,
hereas fewer than 10% of nonaspirin users shared this
istory. Prior aspirin use was also associated with higher risk
cores for UA/NSTEMI, highlighting its association with a
icker group of patients at baseline. Many of these comorbid
onditions proved to be independent predictors of mortality
fter multivariate analysis and thus explain the difference
etween unadjusted and adjusted mortality (Fig. 3).
Our study also found that prior aspirin use was
ssociated with less severe forms of ACS at the time of
resentation, a finding consistent with those of nearly all
f the previously mentioned studies (9 –11,33) and others
s well (36 –38). Despite the observation that prior
spirin users have more cardiovascular disease and are at
uch higher risk of experiencing an ACS, prior aspirin
sers had fewer STEMIs than nonaspirin users and were
ore likely to present with UA than an NSTEMI.
urthermore, the past 2 decades has seen a dramatic shift
n the predominant type of ACS presentation from
TEMI to more commonly UA/NSTEMI (39,40); it
eems plausible that the increase in the use of aspirin,
mong other cardioprotective medications, may have
ontributed significantly to this trend.
The UA/NSTEMI TIMI risk score, a widely utilized
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Figure 4 Adjusted Odds Ratio of Mortality at the Last Follow-U
Among 66,443 Patients Who Sustained an Acute Cor
Adjusted odds ratios and 95% confidence intervals are shown. Variables from the
were included in the initial logistic model before stepwise backwards selection. Abool that risk stratifies patients after ACS, includes prior tspirin use as an independent risk factor for the compos-
te end point of death/recurrent MI/UR at day 14 (31).
lthough the present study shows that prior aspirin use is
ot an independent risk factor for mortality, prior aspirin
se was a modest predictor of nonfatal events, such as
I, RI, and the composite end point of death/recurrent
I/UR/RI/stroke, consistent with its presence as a
ariable in the UA/NSTEMI TIMI risk score. The
resence of confounding by indication and comorbid
onditions likely drives a substantial amount of this risk,
s evidenced by the lower adjusted ORs of all the clinical
utcome end points as compared with the unadjusted
Rs (Tables 4 and 5). Similarly, whereas prior aspirin use
as associated with an increased risk in unadjusted rates
f TIMI major and minor bleeding, this risk no longer
xisted after multivariate analysis. Despite this, there
oes appear to be a modest amount of residual risk of
onfatal events among prior aspirin users, even after
orrecting for such variables.
Some have linked the higher cardiovascular event rate
een in prior aspirin users to the potential of aspirin
esistance (41). It is important to distinguish aspirin resis-
ance from aspirin failure, which can be defined as any
hrombotic event occurring despite aspirin therapy (41).
rue aspirin resistance should require demonstration of the
ersistence of thromboxane synthesis despite aspirin use and
as been shown to occur in as few as 2% to 6% of patients
13,42). Thus aspirin resistance would not appear to explain
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Prior Aspirin and ACS Prognosis October 19, 2010:1376–85onclusions
rom the TIMI database of 66,443 patients, we demon-
trate that prior aspirin use is associated with a high-risk
ohort of patients and can thus be considered a clinical
arker of a high-risk group of patients at risk of adverse
vents. However, after multivariate analysis, prior aspirin
se was not associated with increased mortality after an
CS, emphasizing that it is likely more a marker as opposed
o a pathophysiologic factor related to an increased risk.
lthough prior aspirin use was associated with an increase
n the risk of recurrent MI and the composite end point of
eath/recurrent MI/UR/RI/stroke, this may be attributable
o confounders that cannot be corrected for, aspirin resis-
ance, or both. Further research focusing on this subset of
atients who may be resistant to aspirin therapy will be
elpful in better targeting and caring for these high-risk
atients.
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